Co-Authors
This is a "connection" page, showing publications co-authored by Michael Farris and Beverly Levine.
Connection Strength
0.230
-
McLouth LE, Nightingale CL, Levine BJ, Burris JL, McDougall JA, Lycan TW, Gabbard J, Ruiz J, Farris M, Blackstock AW, Grant SC, Petty WJ, Weaver KE. Unmet Care Needs and Financial Hardship in Patients With Metastatic Non-Small-Cell Lung Cancer on Immunotherapy or Chemoimmunotherapy in Clinical Practice. JCO Oncol Pract. 2021 Feb 04; OP2000723.
Score: 0.049
-
Steber C, Hughes RT, McTyre ER, Soike M, Farris M, Levine BJ, Pasche B, Levine E, Blackstock AW. Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer. Cureus. 2021 Jan 08; 13(1):e12574.
Score: 0.048
-
Ahmed T, Lycan T, Dothard A, Ehrlichman P, Ruiz J, Farris M, Topaloglu U, Levine B, Grant S, Klepin HD, Petty WJ. Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 07; 21(4):e286-e293.
Score: 0.045
-
Steffen McLouth LE, Lycan TW, Levine BJ, Gabbard J, Ruiz J, Farris M, Grant SC, Pajewski NM, Weaver KE, Petty WJ. Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice. Clin Lung Cancer. 2020 05; 21(3):255-263.e4.
Score: 0.045
-
Hughes RT, Helis CA, Soike MH, Levine BJ, Farris M, Blackstock AW. Moderately Hypofractionated Radiotherapy Alone for Stage I-IIB Non-small Cell Lung Cancer. Cureus. 2019 Jun 22; 11(6):e4969.
Score: 0.043